Effect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure

Antagonist Therapy

Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure

Circulation Cardiovascular Quality and Outcomes ◽

10.1161/circoutcomes.116.002946 ◽

2017 ◽

Vol 10 (1) ◽

Cited By ~ 12

Author(s):

Lauren B. Cooper ◽

Bradley G. Hammill ◽

Eric D. Peterson ◽

Bertram Pitt ◽

Matthew L. Maciejewski ◽

...

Keyword(s):

Heart Failure ◽

High Risk ◽

Receptor Antagonist ◽

Antagonist Therapy ◽

Therapy Initiation ◽

Patients With Heart Failure ◽

Risk Patients

Guideline Concordance of Testing for Hyperkalemia and Kidney Dysfunction During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure

Circulation Heart Failure ◽

10.1161/circheartfailure.113.000709 ◽

2014 ◽

Vol 7 (1) ◽

pp. 43-50 ◽

Cited By ~ 13

Author(s):

Larry A. Allen ◽

Susan M. Shetterly ◽

Pamela N. Peterson ◽

Jerry H. Gurwitz ◽

David H. Smith ◽

...

Keyword(s):

Heart Failure ◽

Receptor Antagonist ◽

Kidney Dysfunction ◽

Antagonist Therapy ◽

Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials

Clinical Research in Cardiology ◽

10.1007/s00392-019-01500-3 ◽

2019 ◽

Vol 109 (2) ◽

pp. 194-204 ◽

Cited By ~ 8

Author(s):

Susan Stienen ◽

Patrick Rossignol ◽

António Barros ◽

Nicolas Girerd ◽

Bertram Pitt ◽

...

Keyword(s):

Myocardial Infarction ◽

Heart Failure ◽

Acute Myocardial Infarction ◽

Receptor Antagonist ◽

Fibrotic Response ◽

Antagonist Therapy ◽

St Elevation ◽

Infarction Heart

Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure

JAMA ◽

10.1001/jama.2015.11904 ◽

2015 ◽

Vol 314 (18) ◽

pp. 1973 ◽

Cited By ~ 40

Author(s):

Lauren B. Cooper ◽

Bradley G. Hammill ◽

Eric D. Peterson ◽

Bertram Pitt ◽

Matthew L. Maciejewski ◽

...

Keyword(s):

Heart Failure ◽

Receptor Antagonist ◽

Laboratory Monitoring ◽

Antagonist Therapy ◽

Laboratory Monitoring after Inpatient and Outpatient Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients with Heart Failure

Journal of Cardiac Failure ◽

10.1016/j.cardfail.2016.06.087 ◽

2016 ◽

Vol 22 (8) ◽

pp. S26

Author(s):

Lauren B. Cooper ◽

Bradley G. Hammill ◽

Eric D. Peterson ◽

Bertram Pitt ◽

Matthew L. Maciejewski ◽

...

Keyword(s):

Heart Failure ◽

Receptor Antagonist ◽

Laboratory Monitoring ◽

Antagonist Therapy ◽

Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?

European Journal of Heart Failure ◽

10.1002/ejhf.814 ◽

2017 ◽

Vol 19 (8) ◽

pp. 974-986 ◽

Cited By ~ 20

Author(s):

João Pedro Ferreira ◽

Robert J. Mentz ◽

Anne Pizard ◽

Bertram Pitt ◽

Faiez Zannad

Keyword(s):

Heart Failure ◽

Receptor Antagonist ◽

Antagonist Therapy ◽

Heart Failure Patients ◽

Personalized Approach

Efficacy and safety of mineralocorticoid receptor antagonist therapy in heart failure with reduced ejection fraction

Current Research Cardiology ◽

10.4172/2368-0512.1000012 ◽

2014 ◽

Vol 1 (2) ◽

Author(s):

Arden R Barry ◽

Sheri L Koshman

Keyword(s):

Heart Failure ◽

Ejection Fraction ◽

Receptor Antagonist ◽

Efficacy And Safety ◽

Antagonist Therapy ◽

Reduced Ejection Fraction

Interaction Between Mineralocorticoid Receptor Antagonist and Soluble ST2 in Heart Failure with Preserved Ejection Fraction

Journal of Cardiac Failure ◽

10.1016/j.cardfail.2017.08.062 ◽

2017 ◽

Vol 23 (10) ◽

pp. S20

Author(s):

Akinori Sugano ◽

Yoshihiro Seo ◽

Tomoko Ishizu ◽

Masayoshi Yamamoto ◽

Yoshie Hamada ◽

...

Keyword(s):

Heart Failure ◽

Ejection Fraction ◽

Receptor Antagonist ◽

Preserved Ejection Fraction ◽

Soluble St2

Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease

European Journal of Heart Failure ◽

10.1002/ejhf.218 ◽

2015 ◽

Vol 17 (2) ◽

pp. 224-232 ◽

Cited By ~ 54

Author(s):

Bertram Pitt ◽

Stefan D. Anker ◽

Michael Böhm ◽

Mihai Gheorghiade ◽

Lars Køber ◽

...

Keyword(s):

Heart Failure ◽

Chronic Kidney Disease ◽

Chronic Heart Failure ◽

Kidney Disease ◽

Receptor Antagonist ◽

Mineralocorticoid Receptor Antagonist

Randomized Study ◽

Epithelial Sodium Channel Genotype Is Associated with Elevated Potassium among Patients with Heart Failure Taking a Mineralocorticoid Receptor Antagonist

Journal of Cardiac Failure ◽

10.1016/j.cardfail.2013.06.185 ◽

2013 ◽

Vol 19 (8) ◽

pp. S56

Author(s):

Alexandra Goncharenko ◽

Andrew Kadlec ◽

Adam Bress ◽

Shitalben Patel ◽

Orly Vardeny ◽

...

Keyword(s):

Heart Failure ◽

Sodium Channel ◽

Receptor Antagonist ◽

Epithelial Sodium Channel ◽